1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

Benjamin Solomon, Alexander Drilon, W. Marston Linehan, Lyudmila Bazhenova, Keiko Goto, J. De Langen, Dongwook Kim, Jennifer Moriatis Wolf, Christoph Springfeld, Sanjay Popat, Wan‐Teck Lim, Christina S. Baik, Alice Hervieu, V. Moreno Garcia, Nong Yang, S. Thamake, Felipe Ades, D. Trone, Benjamin Besse